logo
Plus   Neg
Share
Email

Stock Alert: Moderna Jumps 5% On $1.5 Bln Coronavirus Vaccine Deal With U.S. Govt

Shares of Moderna, Inc. (MRNA) are currently gaining over 5% on Wednesday morning. Yesterday, the company signed a $1.5 billion deal with the U.S. government for the supply of its experimental coronavirus vaccine.

MRNA is currently trading at $72.46, up $3.49 or 5.06%, on the Nasdaq.

Moderna reached an agreement with the U.S. to initially supply 100 million doses of its experimental vaccine for COVID-19, mRNA-1273. The U.S. government has awarded up to $1.525 billion for the vaccine.

The U.S. will also have the option to purchase up to an additional 400 million doses of mRNA-1273 from Moderna.

The U.S. government has already invested $955 million in the company's vaccine development, bringing its total investment up to $2.48 billion, Moderna said in a statement.

Moderna's mRNA-1273 is one of the few drugs that are in the final stage of testing and is on track to be completed in September.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Shares of Volkswagen Group were gaining around 3 percent in German trading after the automotive giant Thursday reported market recovery in the third quarter with improved deliveries in the month of September. For the first nine months of fiscal 2020, the company, meanwhile reported sharply lower earnings with weak revenues and sales volume. Comcast Corp. on Thursday reported a 37 percent decline in profit for the third quarter from last year, hurt primarily by revenue decline at NBCUniversal. Both adjusted earnings per share and quarterly revenues topped analysts' expectations. The company also declared a quarterly dividend. In the pre-market trade, CMCSA is trading at $42.83, up $0.85 or 2.02 percent. Regeneron announced positive results from its late stage COVID-19 outpatient trial, indicating that its antibody cocktail therapy significantly reduced virus levels and need for further medical attention. The trial results showed that investigational antibody cocktail, REGN-COV2, met the primary and key secondary endpoints.
Follow RTT